Why is NovoCure Limited (NVCR) stock up today?

NovoCure shares jumped approximately 28% to $20.00 on July 23, 2026 — against a broader market that was firmly in the red — after the company reported record second-quarter revenue of $183.6 million, well ahead of analyst estimates. The company also posted a quarterly loss of $0.13 per share, far better than the consensus estimate of a $0.30 loss and dramatically improved from the $0.36 loss per share in the same quarter a year ago. That earnings-and-revenue double beat is the dominant catalyst for the move: investors who had been positioned for a worse result scrambled to buy the stock, driving the sharp gap higher at the open.

The primary driver of the revenue record was growth in the company's TTFields (tumor treating fields) therapy, a non-invasive cancer treatment delivered through Novocure's Optune device platform. Expansion of Optune's reach across approved indications appears to have accelerated sales meaningfully compared to recent quarters. The company also raised its 2026 revenue guidance following the results, signaling management's confidence that the growth trend can continue through the rest of the year.

The move stands out because it came on a difficult day for the broader market — the S&P 500 fell 1.21% and the Nasdaq-100 (QQQ) dropped 1.88% on the same session. NovoCure's roughly 28% gain was therefore driven almost entirely by its own earnings results rather than any tailwind from general market conditions. Benzinga noted that NovoCure was one of the standout gainers among health care stocks during Thursday's intraday session, with shares cited as up roughly 25–28% while the broader tape was broadly lower.

As of the close, NovoCure's market capitalization stood at approximately $2.32 billion. The stock has had a difficult multi-year run — down more than 90% over the prior five years according to web search data — so today's move represents a significant single-session recovery, though the shares remain deeply below longer-term highs. The company continues to operate at a loss, but the narrowing of that loss and the raised guidance are what the market is reacting to right now.